ArticleBMC complementary medicine and therapies2025
Chitosan nanocarriers loaded with Egyptian Calligonum comosum L'Hér. Extract: an eco-friendly approach for investigating triple-action biological activities.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCalligonum comosum L'Hér. is a large perennial shrub that grows in the desert. This plant inhabits much of the Egyptian desert, but has not yet been scientifically validated. Herein, we demonstrate the antimicrobial, anti-inflammatory, antioxidant, and anticancer properties of the ethanolic extract of the Egyptian C. comosum (CE) and its novel eco-friendly chitosan nano-formula (CE/CsNPs), which is prepared using citrate as a crosslinker.
methodsThe produced plant ethanolic extract (CE) was chemically analyzed. The eco-friendly CE/CsNPs were successfully developed through the conjugation of CE with different concentrations (200, 350, and 400 mg/100 mL) within the chitosan nanoparticle; then, it was fully characterized for the determination of the optimum formula and followed by the assessment of the antioxidant effects, proinflammatory cytokines, evaluation of cytotoxicity against different types of cancer cell lines, and estimation of antimicrobial effects of CE and CE/CsNPs.
resultsThe eco-friendly CE/CsNPs-2 encapsulating 350 mg of CE was selected for the in vitro studies, as it displayed NPs with a small size and a surface charge of 37.7 ± 1.91 mV with the best encapsulation efficiency (70.15 ± 1.58%) within the CsNPs, and it showed a good release profile. Transmission electron microscope (TEM) images confirmed the discrete spherical shape of CE/CsNPs-2, with no aggregations, and revealed a size range of 49.69 to 71.93 nm. FTIR displayed the successful incorporation of CE into the eco-friendly CsNPs. Regarding their biological activity, CE/CsNPs have superior efficacy with high cytotoxicity against cancer cell lines and antioxidant effects. RT-qPCR gene expression assessments displayed that CE/CsNPs resulted in a remarkable downregulation of the inflammatory cytokines' mRNA transcript levels (p < 0.05). It enhanced the antimicrobial effect, with an inhibition zone of 12.34 ± 0.75 mm for Escherichia coli, 16.41 ± 1.01 mm for Staphylococcus aureus, and 18.74 ± 1.13 mm for Candida albicans.
conclusionsThe CE possesses various biological activities, and the developed CE/CsNPs could serve as an appealing formulation to be further investigated for use in anticancer regimens.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.